Trials / Active Not Recruiting
Active Not RecruitingNCT06198751
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 6.0 mg/kg of TQB2102 for injection | TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg. |
| DRUG | 7.5 mg/kg of TQB2102 for injection | TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg. |
Timeline
- Start date
- 2024-02-05
- Primary completion
- 2025-05-08
- Completion
- 2028-02-01
- First posted
- 2024-01-10
- Last updated
- 2025-08-19
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06198751. Inclusion in this directory is not an endorsement.